Kwality Pharmaceuticals gets nod to start pre-clinical toxicity studies for Erythropoietin product

02 Jan 2025 Evaluate

Kwality Pharmaceuticals has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD).

This milestone marks a significant step forward in its commitment to expanding its biologics portfolio and addressing critical healthcare needs. With this approval, the company is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal. 

Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.


Kwality Pharma Share Price

749.35 39.15 (5.51%)
25-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1766.00
Dr. Reddys Lab 1180.55
Cipla 1510.65
Lupin 2068.70
Zydus Lifesciences 907.45
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...